KR930003905A - 약학적 결합 제제 - Google Patents

약학적 결합 제제 Download PDF

Info

Publication number
KR930003905A
KR930003905A KR1019920013983A KR920013983A KR930003905A KR 930003905 A KR930003905 A KR 930003905A KR 1019920013983 A KR1019920013983 A KR 1019920013983A KR 920013983 A KR920013983 A KR 920013983A KR 930003905 A KR930003905 A KR 930003905A
Authority
KR
South Korea
Prior art keywords
formulation
diltiazem
pharmaceutically acceptable
acceptable salt
film coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019920013983A
Other languages
English (en)
Korean (ko)
Inventor
리챠드 벅스톤 이안
브라운 아드리안
크리츨리 헬렌
토마스 레슬리에 스트워트
떼레세 안토이네트 말코우스카 산드라
알란 프라터 데렉
브라운 밀러 로널드
Original Assignee
원본미기재
유로셀티크 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 유로셀티크 에스.에이. filed Critical 원본미기재
Publication of KR930003905A publication Critical patent/KR930003905A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1019920013983A 1991-08-12 1992-08-04 약학적 결합 제제 Ceased KR930003905A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9117361.7 1991-08-12
GB919117361A GB9117361D0 (en) 1991-08-12 1991-08-12 Oral dosage form

Publications (1)

Publication Number Publication Date
KR930003905A true KR930003905A (ko) 1993-03-22

Family

ID=10699854

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920013983A Ceased KR930003905A (ko) 1991-08-12 1992-08-04 약학적 결합 제제

Country Status (14)

Country Link
US (1) US5508044A (cg-RX-API-DMAC10.html)
EP (1) EP0527638A1 (cg-RX-API-DMAC10.html)
JP (1) JPH05201866A (cg-RX-API-DMAC10.html)
KR (1) KR930003905A (cg-RX-API-DMAC10.html)
CN (1) CN1069191A (cg-RX-API-DMAC10.html)
AU (1) AU658209B2 (cg-RX-API-DMAC10.html)
CA (1) CA2075355A1 (cg-RX-API-DMAC10.html)
FI (1) FI923581L (cg-RX-API-DMAC10.html)
GB (1) GB9117361D0 (cg-RX-API-DMAC10.html)
IL (1) IL102777A (cg-RX-API-DMAC10.html)
IN (2) IN173839B (cg-RX-API-DMAC10.html)
NO (1) NO300797B1 (cg-RX-API-DMAC10.html)
PH (1) PH30666A (cg-RX-API-DMAC10.html)
ZA (2) ZA926019B (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
JPH08143450A (ja) * 1994-11-14 1996-06-04 Taiyo Yakuhin Kogyo Kk 徐放化製剤
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
CN1103592C (zh) * 1996-05-22 2003-03-26 永光制药有限公司 含有2－(苯基亚氨基)－3－苯基－1,3－全氢噻嗪的药物组合物及其应用和制备方法
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
GB0007419D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
DE17154462T1 (de) 2002-04-05 2019-12-19 Euro-Celtique S.A. Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20080096979A1 (en) * 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2671197A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
CA2703365A1 (en) * 2007-10-25 2009-04-30 Yuka Yamanouchi Nifedipine-containing press coated tablet and method of preparing the same
ME03298B (me) 2009-03-10 2019-07-20 Euro Celtique Sa Farmaceutske kombinacije sa trenutnim oslobađanjem које obuhvataju oksikodon i nalokson
MX2011011480A (es) * 2009-05-01 2012-02-28 Aptalis Pharmatech Inc Composicines de tabletas que se desintegran oralmente que comprenden combinaciones de analgesicos no opioides y opioides.
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
FI101344B1 (fi) * 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
DK0565634T3 (da) * 1990-12-14 1999-09-27 Smithkline Beecham Corp Angiotensin-II-receptorblokkersammensætninger
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation

Also Published As

Publication number Publication date
CN1069191A (zh) 1993-02-24
IL102777A0 (en) 1993-01-31
CA2075355A1 (en) 1993-02-13
GB9117361D0 (en) 1991-09-25
ZA926019B (en) 1993-03-10
FI923581A7 (fi) 1993-02-13
AU658209B2 (en) 1995-04-06
IN173839B (cg-RX-API-DMAC10.html) 1994-07-23
IN173847B (cg-RX-API-DMAC10.html) 1994-07-23
AU2087992A (en) 1993-02-18
FI923581A0 (fi) 1992-08-11
ZA926020B (en) 1993-03-10
NO923127D0 (no) 1992-08-11
US5508044A (en) 1996-04-16
FI923581L (fi) 1993-02-13
IL102777A (en) 1996-05-14
NO300797B1 (no) 1997-07-28
PH30666A (en) 1997-09-16
NO923127L (no) 1993-02-15
EP0527638A1 (en) 1993-02-17
JPH05201866A (ja) 1993-08-10

Similar Documents

Publication Publication Date Title
KR930003905A (ko) 약학적 결합 제제
KR930003906A (ko) 약학적 구상 제형
US5102668A (en) Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU719170B2 (en) Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
KR920702618A (ko) 약제학적 제형
DE69427568D1 (de) Rasch freisetzende Tablettenkerne mit unlöslichen Arzneistoffen und mit einem Retardüberzug
KR920002135A (ko) 대장에서만 방출할수 있는 피복시킨 고체 약물형태
CA1303504C (en) Pharmaceutical formulation containing acrivastine
BR9806174A (pt) Péletes tendo um núcleo revestido com um antifúngico e um polìmero
KR890009380A (ko) 서방성 약학제제
KR880000088A (ko) 지속적인 방출 제제
KR870002832A (ko) 제약 조성물
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
NO975218L (no) Behandling av inflammatorisk tarmsykdom ved bruk av orale doseringsformer av omega-3-polyumettede syrer
CA2124012A1 (fr) Formulation de diltiazem a liberation prolongee
KR870000069A (ko) 안정한 고체 제형의 제조 방법
KR860006984A (ko) 서방성 제제의 제조방법
CA2021574A1 (en) Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
JPH08506802A (ja) 波状粒薬配給システム
KR900015734A (ko) 코어막 흡착 특성이 향상된, 약제학적으로 허용되는 활성성분을 함유하는 삼투성 연속 방출 경구 전달 시스템
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
US5589190A (en) Sustained-release compositions of alfuzosin hydrochloride
ATE79026T1 (de) Feste pharmazeutische retardform.
CA1251731A (en) Sustained release tablets and method for preparation thereof
BG61751B1 (bg) Форма за контролирано освобождаване на лекарствена дисперсия

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920804

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970212

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920804

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19981210

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19990211

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19981210

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I